EP2971048A2 - Engineered anti-tgf-beta antibodies and antigen-binding fragments - Google Patents
Engineered anti-tgf-beta antibodies and antigen-binding fragmentsInfo
- Publication number
- EP2971048A2 EP2971048A2 EP14779440.8A EP14779440A EP2971048A2 EP 2971048 A2 EP2971048 A2 EP 2971048A2 EP 14779440 A EP14779440 A EP 14779440A EP 2971048 A2 EP2971048 A2 EP 2971048A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- antigen
- antibody
- binding fragment
- human
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 title claims abstract description 218
- 239000012634 fragment Substances 0.000 title claims abstract description 176
- 239000000427 antigen Substances 0.000 title claims abstract description 173
- 102000036639 antigens Human genes 0.000 title claims abstract description 173
- 108091007433 antigens Proteins 0.000 title claims abstract description 173
- 238000006467 substitution reaction Methods 0.000 claims description 107
- 108010032595 Antibody Binding Sites Proteins 0.000 claims description 82
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 201000010099 disease Diseases 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 150000007523 nucleic acids Chemical class 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 230000009870 specific binding Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 5
- 239000013078 crystal Substances 0.000 abstract description 24
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract description 12
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract description 12
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract description 11
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 abstract description 7
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 abstract description 7
- 238000013461 design Methods 0.000 abstract description 3
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 abstract 2
- 101500025624 Homo sapiens Transforming growth factor beta-2 Proteins 0.000 abstract 2
- 101500026551 Homo sapiens Transforming growth factor beta-3 Proteins 0.000 abstract 2
- 102000001708 Protein Isoforms Human genes 0.000 description 49
- 108010029485 Protein Isoforms Proteins 0.000 description 49
- 229940024606 amino acid Drugs 0.000 description 38
- 150000001413 amino acids Chemical class 0.000 description 38
- 125000003275 alpha amino acid group Chemical group 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 34
- 102000009618 Transforming Growth Factors Human genes 0.000 description 32
- 210000004602 germ cell Anatomy 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 20
- 238000011282 treatment Methods 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 229910052731 fluorine Inorganic materials 0.000 description 17
- 229910052698 phosphorus Inorganic materials 0.000 description 17
- 229910052721 tungsten Inorganic materials 0.000 description 17
- 238000003556 assay Methods 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 102000008186 Collagen Human genes 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 12
- 230000007423 decrease Effects 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 230000002209 hydrophobic effect Effects 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 206010016654 Fibrosis Diseases 0.000 description 10
- 238000001516 cell proliferation assay Methods 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 230000036515 potency Effects 0.000 description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 9
- 230000004761 fibrosis Effects 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 210000004940 nucleus Anatomy 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000003472 neutralizing effect Effects 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 208000004608 Ureteral Obstruction Diseases 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000003176 fibrotic effect Effects 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000037390 scarring Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000007758 minimum essential medium Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000001165 hydrophobic group Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229910052722 tritium Inorganic materials 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010019668 Hepatic fibrosis Diseases 0.000 description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010042953 Systemic sclerosis Diseases 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- -1 targeting moiety Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- 241000772415 Neovison vison Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000651 myofibroblast Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004475 Arginine Chemical group 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010051113 Arterial restenosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 208000001708 Dupuytren contracture Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007522 Fused Kidney Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 208000035901 Ischaemic ulcer Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102400000401 Latency-associated peptide Human genes 0.000 description 1
- 101800001155 Latency-associated peptide Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 206010030201 Oesophageal ulcer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010068033 Renal fusion anomaly Diseases 0.000 description 1
- 206010038470 Renal infarct Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000133063 Trixis Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 208000012346 Venoocclusive disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000005274 electronic transitions Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 208000028299 esophageal disease Diseases 0.000 description 1
- 208000019064 esophageal ulcer Diseases 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003903 intestinal lesions Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000009242 medullary sponge kidney Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 201000000173 nephrocalcinosis Diseases 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 201000002674 obstructive nephropathy Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 206010038534 renal tuberculosis Diseases 0.000 description 1
- 201000010384 renal tubular acidosis Diseases 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 102220203056 rs753524431 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001134—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- Transforming Growth Factor- ⁇ (TGFP).
- Compositions comprising the antibodies or fragments thereof and methods of using the same for treatment of diseases involving TGFp activity are provided.
- TGFP tissue level of TGFP is believed to be a factor in the development of idiopathic pulmonary fibrosis and myocardial fibrosis, for example. Furthermore, high local tissue levels of TGFp can allow the maintenance and progression of some types of cancer cells. The down-regulation of TGFP signaling therefore can reduce the viability of such tumor cells.
- TGFP isoforms are ⁇ 25 kDa homodimeric molecules with a similar structural framework in which two monomers are covalently linked via a disulfide bridge.
- the mammalian isoforms share a sequence identity of 70-82%, but have non-overlapping activities in vascular development and the regulation of immune cell function.
- Three TGFp isoforms are present in humans: TGFpi , TGFp2, and TGFP3 (Swiss Prot accession numbers P01 137, P081 12, and PI 0600, respectively).
- TGFpl and TGF 3 trigger a cellular signaling cascade upon binding to the extracellular domains of two
- TGFp receptor types I and II transmembrane receptors
- TGFP2 binding is also thought to involve TGFp receptor types I and II, as well as TGF receptor type III.
- Antibody molecules the can bind human TGFpi , TGFp2, and TGFP3 have been generated (e.g., U.S. Patent No. 7,723,486 to Genzyme).
- MAb human IgG4 monoclonal antibody
- GC1008 is a "pan-specific" TGFP neutralizing antibody, because it can neutralize all three human TGFp isoforms. GC1008 binds to human TGFpi , TGFp2, and TGFP3 with similar affinities. The TGFp epitope recognized by GC1008 overlaps the TGFP binding site for TGFP receptor types I and II, which is believed to underlie the neutralizing ability of GC1008.
- Griitter et al. disclose the three dimensional structure of a GC1008 Fab fragment in complex with TGFp3 at a resolution of 3.1 A. The complex consists of a TGFP3 homodimer flanked by two GC1008 Fab fragments.
- Proteopedia entry 3eo0 "Structure of the Transforming Growth Factor-Beta Neutralizing Antibody GC-1008," on the Internet at proteopedia.org/wiki/index.php/3eo0 (last modified Oct. 20, 2012); and Proteopedia entry 3eol, "Structure of the Fab Fragment of GC-1008 in Complex with Transforming Growth Factor-Beta 3,” on the Internet at proteopedia.org/wiki/index.php/3eol (last modified Oct. 20, 2012).
- TGFp-binding antibodies or antigen-binding fragments thereof are disclosed.
- the TGFP-binding antibodies or antigen-binding fragments thereof may be pan-specific for all TGFp isoforms (TGFp 1 , TGFp2 and TGFP3). Such antibodies or antigen-binding fragments thereof may neutralize all TGFp isoforms.
- the TGFp-binding antibodies or antigen-binding fragments thereof may selectively bind human TGFpi , compared to human TGFp2 and human TGFP3, or which selectively bind human TGFp3, compared to human TGFpi and human TGFP2.
- TGFp isoform-specific antagonists may exhibit fewer potential side effects.
- the design of the antibodies or antigen-binding fragments thereof is facilitated by a co-crystal structure of a recombinant Fab fragment of the GC1008 monoclonal antibody, GC1008(Fab) herein, bound to TGFP2 and by another co-crystal structure of the scFv version of GC1008, known as GC1009 or GC1009(scFv) herein, bound to TGF i .
- An isolated antibody or antigen-binding fragment thereof may comprise a variant of a PET1073G12 variable heavy chain (VH) domain (SEQ ID NO: 1) having TGF paratope and non-paratope residues and a PET1073G12 variable light chain (VL) domain (SEQ ID NO: 2) having TGFpi paratope and non-paratope residues,
- VH variable heavy chain
- VL variable light chain
- VH domain comprises up to 20 substitutions of paratope residues and up to 20 substitutions of non-paratope residues
- VL domain comprises up to 20 substitutions of paratope residues and up to 20 substitutions of non-paratope residues
- said antibody or antigen-binding fragment thereof is capable of binding human TGF (TGFp 1 , TGFp2 and TGFp3).
- the antibody or antigen-binding fragment thereof may be capable of binding all three isoforms of human TGFp, including human TGFpi , human TGFp2, and human TGF 3.
- the antibody or antigen-binding fragment thereof may bind all three isoforms of human TGFp with an affinity two-fold, 2.4-fold, three-fold, five-fold, ten-fold, or higher than GC 1008(Fab) or GC 1009(scFv).
- the antibody or antigen-binding fragment thereof may comprise a substitution of the Y27, S30, S31, N32, 152, 154, V55, D56, N59, E74 and/or GlOl residue.
- Y27 may be substituted with Ala, Asp, Glu, Phe, Gly, His, He, Lys, Leu, Met, Asn, Pro, Gin, Arg, Ser, Thr, Val or Trp.
- S30 may be substituted with Ala, Cys, Asp, Glu, Phe, Gly, His, He, Leu, Met, Asn, Pro, Gin, Arg, Thr, Val, Tyr or Trp.
- S31 may be substituted with Ala, Glu, Gly, His, Lys, Leu, Pro, Gin, Arg, Thr, Val or Trp.
- N32 may be substituted with Ala, Asp, Glu, Gly, Leu, Met, Pro, Gin, Arg, Ser, Thr, Val, Trp or Tyr.
- VH domain and/or VL domain may comprise up to 19substitutions of paratope residues.
- the VH domain and/or VL domain may comprise up to substitutions of paratope residues.
- a paratope substitution may be selected from the substitutions set forth in TABLE 5.
- the VH domain and/or VL domain may comprise up to 18substitutions of non-paratope residues.
- the VH domain and/or VL domain may comprise up to 12 substitutions of non-paratope residues.
- the antibody or antigen-binding fragment thereof may be capable of selectively binding human TGFpi, compared to human TGFP2 and human TGFP3.
- the antibody or antigen -binding fragment thereof may selectively bind TGF i with an affinity two-fold, 2.4-fold, three-fold, five-fold, ten-fold, or higher than
- the VH domain and/or VL domain may comprise up to 20 substitutions of paratope residues, preferably up to 19 substitutions of paratope residues, and more preferably up to 12 substitutions of paratope residues.
- a paratope substitution may be selected from the substitutions set forth in TABLE 5.
- the VH domain and/or VL domain may comprise up to 20 substitutions of non-paratope residues, preferably up to 18 substitutions of non-paratope residues, and more preferably up to 12 substitutions of non-paratope residues.
- the antibody or antigen-binding fragment thereof may be capable of selectively binding human TGFP3, compared to human TGFpi and human TGF 2.
- the antibody or antigen-binding fragment thereof may selectively bind TGFP3 with an affinity two-fold, 2.4-fold, three- fold, five-fold, ten-fold, or higher than GC1008(Fab) or GC1009(scFv).
- the VH domain and/or VL domain may comprise up to 20 substitutions of paratope residues, preferably up to 19 substitutions of paratope residues, and more preferably up to 12 substitutions of paratope residues. A paratope substitution may be selected from the substitutions set forth in TABLE 5.
- the VH domain and/or VL domain may comprise up to 20 substitutions of non-paratope residues, preferably up to 18 substitutions of non-paratope residues, and more preferably up to 12 substitutions of non- paratope residues.
- the antibody may be an IgGl, IgG2, or IgG4 antibody, e.g., a variant of the GC1008 monoclonal antibody.
- the antigen-binding fragment thereof may be an scFv, e.g., a variant of GC1009(scFv), or a di-scFv, for example.
- the VH domain may further comprise a human heavy chain constant domain, e.g., an IgGl, IgG2, or IgG4 constant domain
- the VL domain may further comprise a human light chain constant domain, e.g., a ⁇ light chain constant domain.
- the heavy chain constant domain may have the sequence set forth in SEQ ID NO: 3, and the light chain constant domain may have the sequence set forth in SEQ ID NO: 4.
- the antigen-binding fragment in this embodiment can be a Fab, a Fab', or a F(ab') 2 , e.g., a variant of GC1008(Fab).
- An isolated nucleic acid may comprise a nucleotide sequence encoding an antibody or antigen-binding fragment thereof.
- the isolated nucleic acid may be a cDNA.
- a host cell may comprise the isolated nucleic acid.
- a method of making an antibody or antigen-binding fragment thereof may comprise culturing the host cell under suitable conditions to produce the antibody or antigen-binding fragment thereof. The antibody or antigen-binding fragment thereof produced by this method may be purified.
- a composition may comprise one of the aforementioned antibodies or antigen- binding fragments thereof.
- the composition may be a pharmaceutical composition.
- the pharmaceutical composition may comprise a therapeutically effective amount of an antibody or antigen-binding fragment thereof.
- the composition further may comprise one or more biologically active components.
- a method of treating a disease or condition resulting directly or indirectly from TGFp activity in a human may comprise administering a pharmaceutical composition comprising a therapeutically effective amount of an antibody or antigen-binding fragment thereof.
- the disease or condition may be selected from the group consisting of a fibrotic disease, cancer, or an immune-mediated disease.
- An antibody or antigen-binding fragment thereof may be used in the manufacture of a medicament for treatment of a disease or disorder selected from the group consisting of fibrotic disease, cancer, or an immune-mediated disease.
- the treatment of the disease or disorder may comprise neutralizing TGFpi, TGFp2, and/or TGFP3.
- the treatment of the disease or disorder may comprise inhibiting TGFpi, TGFP2, and/or TGFP3 signaling.
- the treatment of the disease or disorder may comprise inhibiting TGFpi-, TGFP2-, and/or TGFp3-mediated fibronectin production, vascular endothelial growth factor (VEGF) production, epithelial cell proliferation, endothelial cell proliferation, smooth muscle cell proliferation, or immunosuppression.
- the treatment of the disease or disorder may comprise increasing natural killer cell activity.
- FIG. 1 depicts the co-crystal structure of GC1008(Fab) and human TGFp2 (SEQ ID NO: 6).
- FIG. 2 depicts the co-crystal structure of GC1009(scFv) and human TGFpl (SEQ ID NO: 5).
- FIG. 3 depicts a portion of the co-crystal structure of GC1009(scFv) VH domain (SEQ ID NO: 1) and human TGFpl (SEQ ID NO: 5).
- FIG. 4 depicts a portion of the co-crystal structure of GC1008(Fab) VH domain (SEQ ID NO: 1) and human TGFp3 (SEQ ID NO: 7).
- FIG. 5 depicts a portion of the co-crystal structure of GC1008(Fab) and human TGFp.
- the heat map analysis of TABLE 7 is visualized with respect to residues Y27, S30, S31, N32, 152, P53, 154, V55, D56, N59, E74, G101, V103 and L104 of the heavy chain (SEQ ID NO: 1) and residue A93 of the light chain (SEQ ID NO: 2).
- TGFp-binding antibodies or antigen-binding fragments thereof are variants that comprise a modified VH domain of the GC1008 antibody, where the variants comprise an amino acid substitution of the VH and/or VL domain (SEQ ID NO: 1 and SEQ ID NO: 2, respectively).
- TGF antibodies or antigen-binding fragments thereof may comprise a VH domain with an amino acid substitution that confers comparable or improved binding to human TGFp (TGFpi , TGFP2 and TGFP3) that that observed with the GC1008 antibody.
- TGFp-isoform selective antibodies or antigen-binding fragments thereof can bind human TGFpi selectively, compared to human TGFP2 and human TGFP3, or they can bind human TGFP3 selectively, compared to human TGFpl and human TGFP2.
- Selective binding can be achieved by substituting one or more amino acids of the antibodies or antigen-binding fragments thereof comprising a VH domain (SEQ ID NO: 1).
- “Selective binding” means that the antibody or antigen-binding fragment thereof (i) can bind a specific isoform of human TGFp with a higher affinity than an antibody or antigen-binding fragment thereof that comprises an unmodified VH domain of the GC1008 antibody, and/or (ii) can bind the other TGF isoforms with a lower affinity than an antibody or antigen-binding fragment thereof that comprises an unmodified VH domain of the GC1008 antibody.
- an antibody or antigen-binding fragment thereof that selectively binds the TGFpi isoform can bind TGFpl with a higher affinity than GC1008(Fab) or GC1009(scFv), e.g., two-fold, three-fold, five-fold, ten-fold higher, or more.
- the antibody or antigen-binding fragment thereof alternatively or in addition can bind TGFp2 and TGFp3 with a lower affinity than GC1008(Fab) or GC1009(scFv), e.g., two-fold, three-fold, five-fold, ten-fold lower, or more.
- first element “and/or” a second element means a specific disclosure of the first or second element separately, or the first and second elements in combination.
- the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.
- Antibodies or Antigen-Binding Fragments thereof Antibodies or antigen-binding fragments thereof comprising a modified VH domain of the GC1008 antibody include, but are not limited to, whole antibodies, e.g., IgG, such as IgGl, IgG2, or IgG4, or antigen-binding fragments thereof, e.g., F(ab') 2 , scFv, Fab, or dAb polypeptides.
- Monovalent antigen-binding fragments may include Fab, Fv, scFv, and di-scFv, which are two scFv molecules joined by a peptide linker.
- Antigen-binding fragments may be multivalent, e.g., directed to TGF and another antigen.
- Multivalent fragments include F(ab') 2 and di-scFv, where the two scFv components are composed of different variable domains directed to separate antigens.
- the present antibody or antigen-binding fragment thereof may be a modified GC1008 (a whole human IgG4 antibody), GC1008(Fab) (a Fab fragment of GC 1008), or GC 1009(scFv) (an scFv version of GC 1008).
- GC 1009(scFv) is a recombinantly produced antigen-binding fragment comprising a human heavy chain PET1073G12 VH domain (SEQ ID NO: 1) and a human light chain PET1073G12 VL domain (SEQ ID NO: 2) linked by a peptide linker, which allows the two domains to associate into an antigen binding site.
- GC1008 and GC1009 are disclosed in further detail in U.S. Patent No. 7,723,486 and Grutter (2008).
- amino acid sequence of GC1009(scFv) is set forth below, where the peptide linker of the (Gly 4 /Ser) n motif (SEQ ID NO: 10) is bolded and italicized and the signal peptide is highlighted in gray:
- a “modified” or “variant” variable domain comprises amino acid substitutions, compared to the reference sequence.
- a “variant VH domain of the GC1008 antibody,” for example, may comprise amino acid substitutions compared to the PET1073G12 VH domain with the amino acid sequence set forth in SEQ ID NO: 1.
- the VH domain and/or VL domain may comprise up to 20 substitutions of paratope residues, preferably up to 19 substitutions of paratope residues, and more preferably up to 12 substitutions of paratope residues.
- one of the two domains may comprise a substitution of a paratope residue, while the other domain is unmodified, or both of the domains may comprise paratope residue substitutions.
- a paratope substitution may be selected from the substitutions set forth in TABLE 5.
- Paratope substitutions may cause the modified antibody or antigen-binding fragment to bind a TGFfi isoform selectively, or the substitutions may preserve the pan-specific binding of the antibody or antigen-binding fragment to TGFP isoforms. Both types of paratope substitutions also may be made. For example, a paratope substitution may cause the antibody or antigen-binding fragment to bind a TGFp isoform selectively, while another paratope substitution that preserves pan-specific binding is made to de-immunize the antibody or antigen-binding fragment. De-immunization can be performed according to the method of Harding et al. (2010) mAbs 2: 256-265, for example.
- the VH domain and/or VL domain alternatively or in addition may comprise up to 20 substitutions of non-paratope residues, preferably up to 18 substitutions of non- paratope residues, and more preferably up to 12 substitutions of non-paratope residues.
- Non-paratope residues may be substituted for various reasons, for example, to increase the thermostability of an antigen-binding fragment, to remove an amino acid residue that is susceptible to oxidation or deamidation, to add an amino acid that can be easily conjugated to a drug or PEG molecules, for example, or to remove a potential carboxylation site.
- Modifications can also include amino acid deletions.
- one or two non-paratope amino acids may be deleted from a variant VH and/or VL domain.
- the deleted amino acids may be from the carboxyl or amino terminal ends of the VH and/or VL domains.
- a variable domain of the present antibodies or antigen-binding fragments thereof comprises three complementarity determining regions (CDRs), each of which is flanked by a framework region (FW).
- CDRs complementarity determining regions
- a VH domain may comprise a set of three heavy chain CDRs, HCDRl, HCDR2, and HCDR3.
- a VL domain may comprise a set of three light chain CDRs, LCDRl, LCDR2, and LCDR3.
- a set of HCDRs disclosed herein can be provided in a VH domain that is used in combination with a VL domain.
- a VH domain may be provided with a set of HCDRs as disclosed herein, and if such a VH domain is paired with a VL domain, then the VL domain may be provided with a set of LCDRs disclosed herein.
- the structures and locations of immunoglobulin variable domain CDR and FW regions are determined herein by reference to Kabat et al. (1987) Sequences of Proteins of Immunological Interest, 4 th ed., U.S. Department of Health and Human Services.
- the present antibodies or antigen-binding fragments thereof contain "paratope” and "non-paratope” amino acid residues.
- a "paratope” amino acid of a present antibody or antigen-binding fragment thereof has an atomic nucleus within 4 A of an atomic nucleus of human TGFp isoform. Because each human TGF isoform forms a structurally different complex with the present antibodies or antigen-binding fragments thereof, the paratope residues may be different for each isoform.
- a "TGFpi paratope residue,” for example, has an atomic nucleus within 4 A of an atomic nucleus of human TGFpi .
- TABLE 3 shows paratope residues of the present antibodies or antigen-binding fragments thereof for each of the human TGFpi , TGFp2, and TGFP3 isoforms.
- a "TGFp paratope” residue has an atomic nucleus within 4 A of an atomic nucleus of all three human TGFp isoforms.
- a residue is designated a paratope residue irrespective of location within a CDR or FW region, as defined by the Kabat nomenclature. Many paratope residues are located within CDR regions, as shown in TABLE 4, for example. However, some paratope residues are located within the FW regions.
- a “non-paratope” amino acid is any amino acid of the antibody or antigen-binding fragment thereof that is not a "paratope” amino acid, irrespective of whether the residue is located in a CDR or FW region.
- Antibodies or antigen-binding fragments thereof may comprise heavy chain and light chain amino acid substitutions selected from different human germlines.
- a set of HCDRs may be introduced into a repertoire of variable domains lacking CDRs using recombinant DNA technology.
- Germline frameworks include heavy chain sequences from the human DP- 10 (VH 1-69) germline or human DP-88 (VH 1-e) from the VH-1 family.
- Light chain sequences may be from the human VK3 family, e.g., human DPK-22 (A27).
- Human germline variable domain amino acid sequences are disclosed by VBASE2 on the Internet at vbase2.org/vbstat.php, for example.
- a set of HCDRs and a set of LCDRs can be paired together for the PET1073G12, PET1074B9, or PET1287A10 antibodies.
- the antibody thus can be an IgG4 antibody molecule comprising a modified PET1073G12 VH domain and/or PET1073G12 VL domain, for example.
- the amino acid sequences of the PET1073G12, PET1074B9, or PET1287A10 domains, including the HCDR and LCDR sets, are disclosed in U.S. Patent
- Antigen-binding fragments may further comprise antibody constant regions or parts thereof.
- a VL domain may be attached at its C-terminal end to antibody light chain constant domains including human C K or C ⁇ chains.
- an antibody or antigen-binding fragment thereof comprising a VH domain may further comprise attached at its C-terminal end all or part of an immunoglobulin heavy chain
- a CHI domain derived from any antibody isotype, e.g., IgG, IgA, IgE, and IgM, or any of the isotype sub-classes, particularly IgGl, IgG2, or IgG4.
- IgG4 is preferred for some applications because it does not bind complement and does not create effector functions. Where an effector function is desired, IgGl is preferred.
- the antibody constant regions or parts thereof may be human sequences. Modifications can be made to the antibody constant regions to improve various properties of the antibodies or antigen-binding fragments thereof. For example, recombinant amino acid modifications can be used to decrease structural homogeneity of the expressed polypeptides.
- a representative example is Peters et al. (2012) J. Biol. Chem. 287(29): 24525-33, which discloses Cys to Ser substitutions in the IgG4 hinge region that reduce the disulfide bond heterogeneity and increase Fab domain thermal stability.
- Zhang et al. (2010) Anal. Chem. 82: 1090-99 disclose engineering the IgG2 hinge region to limit disulfide bond scrambling and the formation of structural isomers in therapeutic applications.
- Amino acid modifications to a CH3 domain also can be used to delete carboxy-terminal Lys residues to decrease the number of charge variants. Amino acid modifications also can be used to improve the pharmacological function of recombinant antibodies or antigen-binding fragments thereof.
- amino acid modifications can be used to increase complement activation, enhance antibody- dependent cellular cytotoxicity (ADCC) by increasing FcyRIIIA binding or decreasing FcyRIIIB binding, and/or increase serum half-life by increasing FcRn binding.
- ADCC enhance antibody- dependent cellular cytotoxicity
- Such amino acid modifications are reviewed in Beck et al. (2010) Nature 10: 345-52, for example.
- PET1073G12 VH domain (SEQ ID NO: 1); CHI domain (SEQ ID NO: 3); PET1073G12 VL domain (SEQ ID NO: 2); and CK domain (SEQ ID NO: 4), which are present in GC1008(Fab).
- the various CDR and framework (FW) regions are labeled; CDR residues also are highlighted.
- Antibodies or antigen-binding fragments thereof may be mono-specific for human TGF , or they may be bi-specific.
- Bi-specific antibodies or antigen-binding fragments thereof can be manufactured in a variety of ways, as disclosed, for example, in Holliger et al. (1993) Current Opinion Biotechnol.4, 446-449.
- Examples of bi-specific antibodies include those of dual variable domain IgG (DvD-IgG) technology or the BiTETM technology, where the binding domains of two antibodies with different specificity can be used and directly linked via short flexible peptides.
- the heavy chain and/or light chain variable domain of the present antibodies or antigen-binding fragments thereof may be modified recombinantly to alter the amino acid sequence from a germline sequence.
- one or more of the CDRs in the heavy chain CDR set may be modified, one or more CDRs of the light chain CDR set may be modified, and/or one of the framework regions in the VH and/or VL domains may be modified.
- Substitutions can be made to paratope amino acids, for example, that strengthen or weaken the binding affinity to a TGFp isoform, or they can leave the binding affinity relatively unchanged.
- substitutions can be made to non-paratope amino acid residues to confer various characteristics on the antibodies or antigen-binding fragments thereof, e.g., improving stability or introducing a reactive group of the domain surface that can be covalently modified.
- the following four categories of amino acid substitutions to the VH and/or VL domain of the present antibodies or antigen-binding fragments thereof are among those contemplated herein: (1) substitutions that confer selective binding to a human TGFp isoform; (2) substitutions that maintain the pan-specific binding to all three human TGFp isoforms; (3) substitutions to non- paratope amino acids ; and (4) multiple amino acid substitutions. These categories of amino acid substitutions are not mutually exclusive.
- TGFp-isoform selective antibodies or antigen-binding fragments thereof may comprise an amino acid substitution within the VH domain (SEQ ID NO: 1).
- the antibodies or antigen-binding fragments thereof can bind human TGFpl selectively, compared to human TGFp2 and human TGFp3, or can selectively bind human TGFp3, compared to human TGFpl and human TGFP2.
- Selective binding can be achieved substituting one or more paratope amino acids. Predicting how an amino acid substitution will affect the ability of an antibody or antigen-binding fragment thereof to interact with a TGFp isoform is facilitated by a co- crystal structure with each of the TGF isoforms.
- GC1008(Fab) and TGFp3 is disclosed in Grutter (2008).
- the co-crystal structure of GC 1008(Fab) and TGFp2 is depicted in FIG. 1.
- the co-crystal structure of GC 1008(Fab) and TGFp2 is depicted in FIG. 1.
- GC1009(scFv) and TGFpl is depicted in FIG. 2.
- TABLE 2 depicts the amino acid sequence of the human TGFpi , TGFP2, and TGFP3 isoforms. Comparison of co-crystal structures reveals differences in the
- TGFp residues in each isoform that interact with GC1008 are bolded in TABLE 2.
- TGFp3 ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPC YLRSADTTHST
- GC1008 residues interacting with the "tip" and the "helix three” regions show more variability.
- GC1008 shifts orientation and adjusts the CDR loop positions and side chain conformations to accommodate all three TGF isoforms with similar affinity. See FIG. 1 and FIG. 2.
- Grutter (2008) disclosed that GC1008 displayed similar affinities for the three isoforms: IC 50 values of 1 ⁇ 2 nM, 14 ⁇ 5 nM, and 7 ⁇ 2 nM against TGFpi, TGFp2, and TGFP3, respectively in a mink lung epithelial cell (MLEC) proliferation assay.
- MLEC mink lung epithelial cell
- residues 67 and 68 of the three TGFp isoforms differ in their interactions with the VH paratope residue Y27.
- the VH residue Y27 makes hydrogen-bonding interactions with TGFpi residues Q67 and H68.
- VH residue Y27 forms hydrophobic interactions with T67 and Y50 of TGFP2 and TGFp3. This causes a rearrangement of the HCDR1 loop in the TGFpi complex, compared to the TGFp2 and TGFp3 complexes.
- TABLE 3 The information in TABLE 3 is reformatted in TABLE 4 to indicate the residues of the VH and VL domains that are within 4 A of an atomic nucleus of TGFP3 in the co- crystal. Paratope residues are bolded. Most, but not all, of the paratope residues are located within the HCDRs.
- VH sequence (SEQ ID NO: 1)
- VL sequence (SEQ ID NO: 2)
- a comparison of co-crystal structures can guide the substitutions to VH and/or VL domain residues to alter the affinity of GC1008 for TGFP isoforms.
- amino acid substitutions can be based on the location of each VH and/or VL residue in the three crystal structures, taking into consideration whether the residue interacts with the antigen or is involved in interactions with other CDRs or structural elements that stabilize the CDR loops.
- 197 on LCDR3 does not directly interact with TGF in any of the three structures; however, 197 faces the interior of the antibody and in a hydrophobic pocket that is also composed of VI 03 and LI 04 of the HCDR3. Since VI 03 and LI 04 are paratopes important for TGFp binding, substitution of 197 with medium or small hydrophobic or weakly polar residues could be tolerated without significantly changing the affinity toward TGFP, e.g., more than ten-fold.
- the helix3 region shows the most variability in epitope sequence. Lysine and arginine at position 60 of TGFpi and TGFp2 cause a rotation of GC1008 bound to TGFpi and TGFp2 as compared to TGFp3. At residues 67 and 68, TGFpl has glutamine and histidine, respectively, instead of threonine and isoleucine/leucine as in TGFP2 and TGFp3 ( Figure 3).
- S30 is mutated to hydrophobic residues such as A, W
- additional hydrophobic interactions with conserved TGFP L64 is favored, and therefore increases the affinity for all three TGFPs.
- TGF i Focused libraries for TGF i for example would only require randomization of positions 27 and 30 of the VH domain (SEQ ID NO: 1).
- the 32 2 (1024) possible mutants would be covered by phage libraries with a library size of only ⁇ 10 5 species.
- the 20 amino acids can be represented by 32 codons with a sequence of NNG/C, with any of the four nucleic acids at the first two positions and G or C at the third position.
- TGFpl and TGFp2 complexed to GC1009/GC1008 Without the crystal structures of TGFpl and TGFp2 complexed to GC1009/GC1008, one would have to randomize all 14 TGFp3-contacting amino acids derived from the TGFp3 complex structure disclosed in Griitter (2008).
- a phage library with a diversity of 32 14 (10 21 ) would not be fully represented in even the best of any known libraries, which present no more than about ⁇ 10 n species.
- the structure data provided herein would allow the rapid screening and identification of TGFP selective antagonists.
- Substitutions can be made that do not significantly alter the binding affinity toward a TGFp isoform.
- a substitution that does not "significantly alter” the binding affinity toward a TGFP isoform does not increase the ratio of the off-rate of the variant (k d var ) compared to the off-rate of the wild-type (k/*) by more than 2.4 (i.e., k ⁇ /k/ 1 is less than or equal to 2.4).
- Antibodies or antigen-binding fragments thereof that display "pan-specific binding" for this purpose can have an apparent binding constant for TGFp (TGFpl , TGFp2 and TGFp3) of at least 10 nM, 30 nM, or 100 nM.
- Affinity for TGFp isoforms can be measured using any appropriate technique in the art, for example, the MLEC proliferation assay disclosed in Griitter (2008) or a Biacore® 3000 (GE)
- Antibodies or antigen-binding fragments thereof that display "pan-specific binding" for this purpose can have an apparent binding affinity (k ar :k d Wt ) for TGFP (TGFpl , TGFP2 and TGFP3) of less than or equal to 2.4-fold, less than or equal to 3-fold, less than or equal to 5-fold, or less than or equal to 10-fold compared to wild type, preferably less than or equal to 2.4-fold compared to wild type (k d var :kd Wt ). These substitutions may be guided by the three co-crystal structures between
- Substitutions having a significant detrimental effect on stability can promote aggregation and inactivation of the antibodies or antigen-binding fragments thereof by causing local unfolding or misfolding.
- the destabilized, aggregated antibodies or antigen-binding fragments thereof can induce immunogenicity, because the patient's immune system can recognize such aggregates as foreign molecules.
- An example of a substitution maintaining pan-specific binding is R24 on LCDR1.
- R24 is oriented away from the TGFp binding site and is exposed on the VL domain surface. This position can accommodate a substitution with most polar residues except Pro and Cys, which are generally avoided.
- 152 on HCDR2 makes a close hydrophobic interaction with the "hydrophobic patch" on TGFp (L 28 GWKW 32 (SEQ ID NO: 8)), so 152 substitutions are restricted to medium size hydrophobic residues, with the possibility of a Val substitution, whereas a substitution with a larger hydrophobic residues could create steric hindrance in the bound complex.
- TABLE 5 provides non-limiting examples of amino acid substitutions of the VL domain of SEQ ID NO: 2 (TABLE 5A)and the VH domain of SEQ ID NO: 1 (TABLE 5B).
- amino acid substitutions may be made to framework residues within the paratope, e.g., VL residue Y50 in the FW2 region.
- Antibodies or antigen-binding fragments with one or more of the substitutions below are expected to have a similar pan- specificity and improved affinity toward TGFp as GC1008/GC1009, i.e., to bind all TGFp isoforms with isoforms with a binding affinity (k ⁇ k *) of less than or equal to 2.4-fold, less than or equal to 3-fold, less than or equal to 5-fold, or less than or equal to 10-fold compared to wild type .
- Non-paratope amino acids can be substituted recombinantly to make a variable light or heavy domain with similar or altered properties compared to the germline variable domain.
- Modified variable domains also include amino acid deletions, as well as substitutions. For example, the N- terminal or C-terminal amino acid residue may be deleted in a modified variable domain.
- Non-paratope amino acid substitutions can be made, for example, to increase the stability and/or decrease the tendency to aggregate. Poor stability can affect the ability of an antigen-binding fragment, for example, to fold properly when recombinantly expressed, resulting in a fraction of the expressed fragments being non-functional. Low stability antibodies or antigen-binding fragments thereof also may be prone to forming potentially immunogenic aggregates or may have impaired avidity or shelf-life. scFv polypeptides in particular may demonstrate problems with stability, solubility, expression, aggregation, breakdown products, and overall manufacturability in both bacterial and mammalian expression systems.
- Framework amino acid substitutions that are expected to increase the stability and/or decrease the tendency to aggregate of a VH and/or VL domain, e.g., in an scFv polypeptide, are disclosed in WO 2007/109254, for example. Substitutions in corresponding residues in the present VH and VL domains are expected similarly to increase stability and/or decrease the tendency to aggregate.
- Substitutions that can be tolerated are expected to include those that would replace a non-paratope amino acid of SEQ ID NO: 1 or 2 with a corresponding amino acid that occurs in another human VH or VL domain germline sequence.
- about 40 variable heavy germline sequences are known in the art, as are about 40 variable kappa germline sequences and about 30 variable lambda germline sequences. A substitution of a non-paratope amino acid with an amino acid occurring in any of these germline sequences is expected to be tolerated.
- a residue of a VH domain of SEQ ID NO: 1 could be substituted with an amino acid appearing in a corresponding position in any VH germline sequence, e.g., the germline sequence from DP-10 (VH 1-69) or DP-88 (VH 1-e).
- Corresponding positions in this case are determined by a sequence alignment between the various germline sequences, using alignment techniques well known in the art, e.g., ClustalW.
- substitutions to amino acids buried within the variable domains will be better tolerated if the side chain of the amino acid does not create steric hindrance with adjoining residues. For this reason, buried amino acids generally are substituted with amino acids with side chains of similar or smaller size. For example, a substitution of a buried He residue with a Leu, Val, Ala, or Gly is expected to be tolerated. Possible steric hindrance created by a substitution can be predicted by analysis of the three co-crystal structures. Further substitutions that are expected to be tolerated are those maintaining existing electrostatic interactions within the variable domains, e.g., dipole-dipole interactions, induced dipole interactions, hydrogen bonds, or ionic bonds.
- variable domains include those expected to confer new useful properties to the antibodies or antigen-binding fragments thereof.
- putative N-glycosylation sites in the VH and/or VL domains can be removed to prevent or reduce the formation of N-glycoforms.
- the amino-terminal residue can be substituted with a Gin residue to cause pyroglutamylation, which can decrease the number of charge variants.
- Amino acid substitutions can be used to lower the isoelectric point, which can decrease the rate of elimination of IgG polypeptide antibodies, for example.
- variable domains can be substituted with Cys or Lys residues, for example, which then can be covalently modified and coupled to molecules conferring useful characteristics to the antibodies or antigen-binding fragments thereof, e.g., a detectable label, toxin, targeting moiety, or protein.
- Cys residue can be coupled to a cytotoxic drug to form a drug conjugate.
- Cys residues also can be coupled to molecules that increase the serum half-life, e.g., polyethylene glycol (PEG) or serum albumin.
- PEG polyethylene glycol
- serum albumin Such amino acid modifications are reviewed in Beck et al. (2010) Nature 10: 345-52, for example.
- Detectable labels include radiolabels such as 13 ⁇ or 99 Tc, which may be attached to antibodies or antigen-binding fragments thereof using methods known in the art.
- Labels also include enzyme labels such as horseradish peroxidase. Labels further include chemical moieties such as biotin which may be detected via binding to a specific cognate detectable moiety, e.g., labeled avidin. Other moieties can be attached that facilitate purification. For example, antibodies or antigen-binding fragments thereof can be His- tagged using well-known methods of recombinant modification and expression.
- the antibodies or antigen-binding fragments thereof are expected to maintain stability and functionality after at least several randomly selected amino acid substitutions. See, e.g., Wells, Biochemistry 29: 8509-17 (1990). However, as more substitutions are randomly introduced into a variable domain, for example, the overall stability of the domain may decrease, its tendency to aggregate may increase, its affinity for TGFp may decrease, and its possible immunogenicity may increase. Thus, when multiple amino acid substitutions are made, preferred substitutions are selected from those described above, which are expected to maintain stability and functionality.
- the functionality of the modified variable domains can be tested using routine methods known in the art, including but not limited to the MLEC proliferation assay disclosed in Grutter (2008). Nucleic Acids and Methods of Making Antibodies and Antigen-Binding Fragments
- a further aspect of the present invention provides nucleic acids encoding antibodies or antigen-binding fragments thereof disclosed herein.
- the isolated nucleic acid may be a synthetic DNA, a non-naturally occurring mRNA, or a cDNA, for example.
- the nucleic acid may be inserted within a plasmid, vector, or transcription or expression cassette.
- a recombinant host cell may comprise one or more constructs above.
- An "isolated" nucleic acid (or antibody or antigen-binding fragment thereof) is removed from its natural environment, and may additionally be in substantially pure, e.g., at least 90% pure, or in homogeneous form.
- Methods of preparing antibodies or antigen-binding fragments thereof comprise expressing the encoding nucleic acid in a host cell under conditions to produce the antibodies or antigen-binding fragments thereof, and recovering the antibodies or antigen-binding fragments thereof.
- the process of recovering the antibodies or antigen- binding fragments thereof may comprise isolation and/or purification of the antibodies or antigen-binding fragments thereof.
- the method of production may comprise formulating the antibodies or antigen-binding fragments thereof into a composition including at least one additional component, such as a pharmaceutically acceptable excipient.
- Suitable vectors comprising a nucleic acid encoding antibodies or antigen-binding fragments thereof can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate.
- Vectors may be plasmids, phage, phagemids, adenoviral, AAV, lentiviral, for example.
- Techniques and protocols for manipulation of nucleic acid for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells, and gene expression, are well known in the art.
- nucleic acids into a host cell can be accomplished using techniques well known in the art.
- suitable techniques may include calcium phosphate transfection, DEAE-Dextran, electroporation, liposome-mediated transfection, and transduction using retroviruses or other viruses, for example.
- suitable techniques may include calcium chloride transformation, electroporation, and transfection using bacteriophage.
- the introduction may be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells under conditions for expression of the gene.
- the nucleic acid of the invention is integrated into the genome, e.g., chromosome, of the host cell. Integration may be promoted by inclusion of sequences which promote recombination with the genome, in accordance with standard techniques.
- Suitable host cells include bacteria, mammalian cells, plant cells, insect cells, fungi, yeast and transgenic plants and animals.
- Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney cells, mouse melanoma cells, rat myeloma cells, human embryonic kidney cells, human embryonic retina cells, and many others.
- CHO Chinese hamster ovary
- HeLa cells HeLa cells
- baby hamster kidney cells mouse melanoma cells
- rat myeloma cells human embryonic kidney cells
- human embryonic retina cells and many others.
- the expression of antibodies and antibody fragments in prokaryotic cells, such as E. coli is well established in the art.
- Antibodies or antigen-binding fragments thereof may be glycosylated, either naturally or the choice of expression host, e.g., CHO or NSO (ECACC 851 10503) cells, or they may be unglycosylated, for example if produced by expression in a prokaryotic cell. Glycosylation may also be intentionally altered, for example by inhibiting fucosylation, in order to increase ADCC activity of the resulting antibody.
- the present antibodies or antigen-binding fragments thereof may be used in a method of treatment or diagnosis of the human or animal body, such as a method of treatment (which may include prophylactic treatment) of a disease or disorder in a human patient, which comprises administering an effective amount to the patient.
- Treatable conditions include any in which TGFp plays a role, e.g., fibrotic disease, cancer, an immune-mediated disease, and wound healing.
- the present antibodies or antigen-binding fragments thereof are useful to treat a disease and condition resulting directly or indirectly from TGFP activity.
- the present antibodies or antigen-binding fragments thereof may selectively inhibit the activity of a human TGFp isoform in vitro or in vivo.
- TGFp iso forms include, but are not limited to, TGFP-mediated signaling, extracellular matrix (ECM) deposition, inhibiting epithelial and endothelial cell proliferation, promoting smooth muscle proliferation, inducing Type III collagen expression, inducing TGF- ⁇ , fibronectin, VEGF, and IL-1 1 expression, binding Latency Associated Peptide, tumor-induced
- the present antibodies or antigen-binding fragments thereof are useful to treat focal segmental glomerulosclerosis (FSGS), hepatic fibrosis (HF), acute myocardial infarction (AMI), idiopathic pulmonary fibrosis (IPF), scleroderma (SSc), and Marfan Syndrome.
- FSGS focal segmental glomerulosclerosis
- HF hepatic fibrosis
- AMI acute myocardial infarction
- IPF idiopathic pulmonary fibrosis
- SSc scleroderma
- Marfan Syndrome Marfan Syndrome
- the antibodies or antigen-binding fragments thereof are useful to treat diseases and conditions including, but not limited to, fibrotic diseases (such as glomerulonephritis, neural scarring, dermal scarring, pulmonary fibrosis, lung fibrosis, radiation induced fibrosis, hepatic fibrosis, myelofibrosis), burns, immune mediated diseases, inflammatory diseases (including rheumatoid arthritis), transplant rejection, cancer, Dupuytren's contracture, and gastric ulcers.
- fibrotic diseases such as glomerulonephritis, neural scarring, dermal scarring, pulmonary fibrosis, lung fibrosis, radiation induced fibrosis, hepatic fibrosis, myelofibrosis
- fibrotic diseases such as glomerulonephritis, neural scarring, dermal scarring, pulmonary fibrosis, lung fibrosis, radiation induced fibrosis, hepatic fibrosis, myel
- renal insufficiencies including but not limited to: diabetic (type I and type II) nephropathy, radiation-induced nephropathy, obstructive nephropathy, diffuse systemic sclerosis, pulmonary fibrosis, allograft rejection, hereditary renal disease (e.g., polycystic kidney disease, medullary sponge kidney, horseshoe kidney),
- tubulointerstitial nephropathy renal tubular acidosis, renal tuberculosis, and renal infarction.
- they are useful when combined with antagonists of the renin- angiotensin-aldosterone system including, but not limited to: renin inhibitors,
- angiotensin-converting enzyme (ACE) inhibitors Ang II receptor antagonists (also known as “Ang II receptor blockers”), and aldosterone antagonists.
- ACE angiotensin-converting enzyme
- Ang II receptor antagonists also known as "Ang II receptor blockers”
- aldosterone antagonists aldosterone antagonists.
- the antibodies or antigen-binding fragments thereof also are useful to treat diseases and conditions associated with the deposition of ECM, including, systemic sclerosis, postoperative adhesions, keloid and hypertrophic scarring, proliferative vitreoretinopathy, glaucoma drainage surgery, corneal injury, cataract, Peyronie's disease, adult respiratory distress syndrome, cirrhosis of the liver, post myocardial infarction scarring, post angioplasty restenosis, scarring after subarachnoid hemorrhage, multiple sclerosis, fibrosis after laminectomy, fibrosis after tendon and other repairs, scarring due to tattoo removal, biliary cirrhosis (including sclerosing cholangitis), pericarditis, pleurisy, tracheostomy, penetrating central nervous system injury, eosinophilic myalgic syndrome, vascular restenosis, veno-occlusive disease, pancreatitis and psori
- the antibodies or antigen-binding fragments thereof further are useful to promote re-epithelialization in diseases and conditions such as venous ulcers, ischaemic ulcers (pressure sores), diabetic ulcers, graft sites, graft donor sites, abrasions and burns, diseases of the bronchial epithelium, such as asthma, ARDS, diseases of the intestinal epithelium, such as mucositis associated with cytotoxic treatment, esophageal ulcers (reflux disease), stomach ulcers, small intestinal and large intestinal lesions
- the antibodies or antigen-binding fragments thereof also may be used to promote endothelial cell proliferation, for example, in stabilizing atherosclerotic plaques, promoting healing of vascular anastomoses, or to inhibit smooth muscle cell
- the antibodies or antigen-binding fragments thereof are useful to enhance the immune response to macrophage-mediated infections. They are also useful to reduce immunosuppression caused, for example, by tumors, AIDS, or granulomatous diseases.
- the antibodies or antigen-binding fragments thereof are useful to treat hyperproliferative diseases, such as cancers including, but not limited to, breast, prostate, ovarian, stomach, renal, pancreatic, colorectal, skin, lung, cervical and bladder cancers, glioma, mesothelioma, as well as various leukemias and sarcomas, such as Kaposi's sarcoma, and are useful to treat or prevent recurrences or metastases of such tumors.
- Antibodies or antigen-binding fragments thereof also are useful to inhibit cyclosporin-mediated metastases.
- treatment includes any medical intervention resulting in the slowing of tumor growth or reduction in tumor metastases, as well as partial remission of the cancer in order to prolong life expectancy of a patient.
- Methods of treatment comprise administering an antibody or antigen-binding fragment thereof or pharmaceutical compositions comprising the antibody or antigeni c) binding fragment thereof.
- the antibody or antigen-binding fragment thereof may be used in the manufacture of a medicament for administration.
- a method of making a medicament or pharmaceutical composition comprises formulating an antibody or antigen-binding fragment thereof with a pharmaceutically acceptable excipient.
- a composition may be administered alone or in combination with other treatments, either 15 simultaneously or sequentially dependent upon the condition to be treated.
- Administration is preferably in a "therapeutically effective amount" sufficient to show benefit to a patient. Such benefit may be at least amelioration of at least one symptom of a particular disease or condition.
- the actual amount administered, and rate and time-course of administration, will depend on the nature and severity of the disease 0 or condition being treated. Prescription of treatment, e.g., decisions on dosage etc., may be determined based on preclinical and clinical studies the design of which is well within the level of skill in the art.
- the precise dose will depend upon a number of factors, including whether the antibody or antigen-binding fragment thereof is for diagnosis or for treatment, the size 5 and location of the area to be treated, the precise nature of the antibody or antigen- binding fragment thereof, e.g., whole antibody, Fab, or scFv fragment, and the nature of any detectable label or other molecule attached to the antibody or antigen-binding fragment thereof.
- a typical dose of a whole antibody for example, can be in the range 100 ⁇ g to 1 gm for systemic applications, and 1 ⁇ g to 1 mg for topical applications.
- Treatments may be repeated at daily, twice- weekly, weekly, monthly or other intervals, at the discretion of the physician. Treatment may be periodic, and the period between administrations is about two weeks or more, preferably about three weeks or more, more preferably about four weeks or more, or about once a month.
- Dose levels of about 0.1, 0.3, 1, 3, 10, or 15 mg per kg body weight of the patient are expected to be useful and safe.
- 0.5-5 mg/kg in rat and mouse has been an effective dose in an acute setting. Therefore, for long-term dosing, 0.3-10 mg/kg may be administered to humans, based on an expected half-life of 21 days.
- Doses may be sufficient for efficacy, while low enough to facilitate optimal administration.
- a dose of less than 50 mg facilitates subcutaneous administration.
- Intravenous administration may be used as the route of delivery for severe diseases, where high doses and the long dosing intervals may be required.
- Subcutaneous injection can increase the potential immune response to a product.
- Local administration for localized disease can reduce the amount of administered product and increase the concentration at the site of action, which can improve safety.
- An antibody or antigen-binding fragment thereof may be administered by injection, for example, subcutaneously, intravenously, intracavity (e.g., after tumor resection), intralesionally, intraperitoneally, or intramuscularly.
- An antibody or antigen- binding fragment thereof also may be delivered by inhalation or topically (e.g., intraocular, intranasal, rectal, into wounds, on skin), or orally.
- Antibodies or antigen-binding fragments thereof will usually be administered in the form of a pharmaceutical composition, which may comprise at least one component in addition to the antibody or antigen-binding fragment thereof.
- pharmaceutical compositions may comprise a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. Such materials could include, for example, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents.
- Some examples of pharmaceutically acceptable carriers are water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof.
- isotonic agents for example, sugars, polyalcohols, such as mannitol, sorbitol, or sodium chloride in the composition.
- additional examples of pharmaceutically acceptable substances are wetting agents or auxiliary substances, such as emulsifying agents, preservatives or buffers, which increase the shelf life or effectiveness.
- the carrier or other material will depend on the route of administration.
- the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pK, isotonicity, and stability.
- isotonic vehicles such as sodium chloride injection, Ringer's injection, and lactated Ringer's injection.
- Preservatives, stabilizers, buffers, antioxidants and/or other additives may be included.
- An antibody or antigen-binding fragment thereof may be formulated in liquid, semi-solid or solid forms such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, powders, liposomes, and suppositories.
- liquid solutions e.g., injectable and infusible solutions
- dispersions or suspensions e.g., dispersions or suspensions
- powders e.g., liposomes, and suppositories.
- suppositories e.g., suppositories.
- the preferred form depends on the intended mode of administration, therapeutic application, the
- Formulations may include excipients, or combinations of excipients, for example: sugars, amino acids and surfactants.
- Liquid formulations may include a wide range of antibody concentrations and pH. Solid formulations may be produced by lyophilization, spray drying, or drying by supercritical fluid technology, for example.
- compositions can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration.
- Sterile injectable solutions can be prepared by incorporating the antibody or antigen- binding fragment thereof in an appropriate solvent with one or a combination of ingredients enumerated above, followed by filtered sterilization.
- dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- the proper fluidity of a solution can be maintained, for example, by using a coating such as lecithin, by maintaining the particle size of a dispersion, or by using surfactants.
- Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example,
- the active compound may be prepared with a carrier that will protect the antibody or antigen-binding fragment thereof against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems.
- a controlled release formulation including implants, transdermal patches, and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art.
- a method of using an antibody or antigen-binding fragment thereof may comprise causing or allowing binding to TGFp.
- binding may take place in vivo, e.g., following administration of an antibody or antigen-binding fragment thereof to a patient, or it may take place in vitro, e.g., in ELISA, Western blotting, immunocytochemistry, immunoprecipitation, affinity chromatography, or cell based assays, or in ex vivo based therapeutic methods, e.g., methods in which cells or bodily fluids are contacted ex vivo with an antibody or antigen-binding fragment thereof and then administered to a patient.
- kits comprising an antibody or antigen-binding fragment thereof.
- the antibody or antigen-binding fragment thereof may be labeled to allow its reactivity in a sample to be determined.
- Kits may be employed in diagnostic analysis, for example.
- a kit may contain instructions for use of the components.
- Ancillary materials to assist in or to enable performing such a method may be included within the kit.
- the reactivity of an antibody or antigen-binding fragment thereof in a sample may be determined by any appropriate means, e.g., radioimmunoassay (RIA).
- Radioactively labeled antigen may be mixed with unlabeled antigen (the test sample) and allowed to bind to the antibody or antigen-binding fragment thereof. Bound antigen is physically separated from unbound antigen and the amount of radioactive antigen bound to the antibody or antigen-binding fragment thereof is determined.
- a competitive binding assay also may be used with non-radioactive antigen, using an antigen or an analogue linked to a reporter molecule.
- the reporter molecule may be a fluorochrome, phosphor, or dye. Suitable fluorochromes include fluorescein, rhodamine, phycoerythrin and Texas Red. Suitable chromogenic dyes include diaminobenzidine.
- Other reporters include macromolecular colloidal particles or particulate material such as latex beads that are colored, magnetic or paramagnetic, and biologically or chemically active agents that can directly or indirectly cause detectable signals to be visually observed, electronically detected or otherwise recorded.
- These molecules may be enzymes that catalyze reactions that develop or change colors or cause changes in electrical properties, for example. They may be molecularly excitable, such that electronic transitions between energy states result in characteristic spectral absorptions or emissions. They may include chemical entities used in conjunction with biosensors. Biotin/avidin or biotin/streptavidin and alkaline phosphatase detection systems may be employed.
- the signals generated by antibody-reporter conjugates may be used to derive quantifiable absolute or relative data of the relevant antibody binding in samples.
- the present invention also provides the use of an antibody or antigen-binding fragment thereof for measuring antigen levels in a competition assay.
- Linking a reporter molecule to the antibody or antigen-binding fragment thereof so that a physical or optical change occurs on binding is one possibility.
- the reporter molecule may directly or indirectly generate detectable, and preferably measurable, signals.
- the linkage of reporter molecules may be directly or indirectly, covalently, e.g., via a peptide bond or non-covalently.
- the antibody or antigen-binding fragment thereof and a protein reporter may be linked by a peptide bond and recombinantly expressed as a fusion protein.
- Anti-TGF single chain Fv may be prepared according to the following non-limiting example disclosed in Example 1 of U.S. Patent No. 7,723,486.
- the neutralization potencies for TGFpl, TGFP2, and/or TGFP3 can be increased using mutagenesis and/or combinatorial techniques.
- scFv with improved potencies for TGFpi, TGFP2, and/or TGFP3 can be generated by selecting and screening phage antibody libraries as described in Example 1 of U.S. Patent No. 7,723,486.
- the scFvs generated in that example were compared to 1D1 1.16, which is disclosed in U.S. Patent No.
- PET1287A10 VH and VL gene segments were aligned to the known human germline sequences in the VBASE database (Tomlinson, V-BASE sequence directory, MRC Centre for Protein Engineering, Cambridge, UK, at hypertext transfer protocol vbase.mrc-cpe.cam.ac.uk (1997)), and the closest human germline was identified by sequence similarity.
- the closest human germline gene for the VH gene segment of PET1073G12 and PET1074B9 was identified as DP-10/1-69 (VHl germline family) and the closest human germline gene for the VH gene segment of PET1287A10 was identified as DP-88/l-e (VHl germline family).
- the closest human germline gene for the VL gene segment of PET1073G12, PET1074B9, and PET1287A10 was identified as DPK22/A27 (V K 3 germline family).
- Site-directed mutagenesis was used to substitute framework residues that differed from germline to the germline residue, provided that such changes did not produce a loss of potency in the MLEC proliferation assay of more than three-fold in the resulting antibody on any TGFp isoform. If such a loss of potency was observed, the non-germline framework amino acid was kept in the final antibody.
- germlined PET1073G12 and germlined PET1074B9 all framework residues are germline except for two residues in VH and one residue in VL.
- the amino acid sequences for germlined PET1073G12 are described in SEQ ID NO: 2 for VH and SEQ ID NO: 7 for VL of U.S. Patent No. 7,723,486.
- the amino acid sequences for germlined PET1074B9 are described in SEQ ID NO: 12 for VH and SEQ ID NO: 17 for VL of U.S. Patent No. 7,723,486.
- germlined PET1287A10 all VH and VL framework residues are germline.
- the amino acid sequences for germlined PET1287A10 are described in SEQ ID NO: 22 for VH and SEQ ID NO: 27 for VL of U.S. Patent No. 7,723,486.
- Neutralization potency of anti-TGFp antibodies or antigen-binding fragments thereof can be assayed using the TGFp dependent MLEC proliferation assay disclosed in Example 4 of U.S. Patent No. 7,723,486.
- the MLEC proliferation assay is based on an assay described by Danielpour et al., J. Cell. Physiol, 138:79-86 (1989). This assay works on the principle that TGFpi, TGFp2, or TGFP3 added to mink lung epithelial cells inhibits serum induced cell proliferation. Antibodies were tested for neutralization of TGF l, TGFp2, or TGFP3 resulting in the restoration of the cell proliferation.
- Proliferation was measured by the uptake of [ 3 H]-thymidine.
- the potency of the antibody was defined as the concentration of the antibody that neutralized a single concentration of TGFp 1 , TGFp2, or TGFp3 at a level of 50% (IC 50 ) in nM.
- MLEC proliferation assay protocol the MLEC line was obtained from the American Type Culture Collection (Cat.# CCL-64). Cells were grown in Minimum Essential Media (MEM, Gibco) containing 10% fetal bovine serum (FBS) (Gibco), 1% penicillin/streptomycin (Gibco) and 1% MEM non-essential amino acids solution
- Confluent cells from T-175 flasks were dissociated from the flask, spun down, washed, and resuspended in MLEC assay media that was made of MEM containing 1% FBS, 1% penicillin / streptomycin and 1% MEM non-essential amino acids solution. An aliquot of the cells was then labeled with trypan blue, counted on a haemocytometer, and the cell stock diluted to 1.75 ⁇ 10 5 cell per ml using assay media. ⁇ ⁇ ⁇ suspension was added to each well of a tissue culture flat-bottomed 96 well plate and incubated for 3 to 5 hours.
- TGFp/antibody solutions Preparation of TGFp/antibody solutions: working solutions of TGFpl, TGFP2, or TGFP3 at 6 ng/ml (six times the final assay concentration) and antibodies (including controls such as 1D1 1.16) at three times the final maximum assay concentration were prepared in MLEC assay media.
- the final concentration of TGF in the assay (1 ng/ml or 40 pM) corresponded to the concentration that induced approximately 80% inhibition of cell proliferation compared to the control with no TGF (i.e., EC 80 value).
- Dilution plate set up samples of test and control antibodies were titrated in 3-fold dilution steps in MLEC assay media and incubated in the presence and absence of TGF i, TGFP2 or TGF 3. All relevant controls were included in every experiment: testing of the ID 1 1.16 and/or reference antibody as appropriate and performing TGF i, TGFP2, or TGFP3 titrations. Completed plates were left in a humidified tissue culture incubator for 1 hour ⁇ 15 minutes. Addition of TGF /antibody solutions to the plated cells: after the appropriate incubation times, 100 from each well of the dilution plates were transferred to the plated MLEC and the plates returned to the incubator for 44 ⁇ 2 hours.
- TGFP isoform binding affinity of the GC1008 antibody was measured using a Biacore® 3000 (GE Healthcare) instrument. TGFpi and TGFp2, produced in-house, were diluted to ⁇ 1 ⁇ g/mL in 10 mM acetate, pH 4.5, and TGFP3
- CM5 sensor chip (R&D Systems) was diluted to ⁇ 2 ⁇ g/mL in 10 mM acetate, pH 4.0.
- Flowcells 2, 3, and 4 of a CM5 sensor chip were covalently immobilized with 50 to 100 RU of TGFpi , TGFP2, and TGFP3, respectively, using the standard amine coupling kit from GE Healthcare.
- Flowcell 1 was used as a control surface.
- GC1008 was serially diluted 1 :3 from 33.3 nM to 1.2 nM in HBS-EP buffer and injected in triplicate to all four flowcells for 5 min, followed by 5 min dissociation in buffer at a 30 ⁇ / ⁇ flow-rate.
- the surface was regenerated with two 30 sec injections of 40 mM HCl at 75 ⁇ /min.
- the sensorgrams were fit using a 1 : 1 binding model after subtraction of buffer and control flowcell refractive index changes with the BIA Evaluation Software K it (GE Healthcare).
- the D'S shown in TABLE 6 are an average of more than 25 independent assays.
- the biologic efficacy of antibodies or antigen-binding fragments thereof for treating chronic renal disease and other clinical indications can be determined using the rat unilateral ureteral obstruction (UUO) model set forth in Example 7 of U.S. Patent No. 7,723,486.
- UUO rat unilateral ureteral obstruction
- Rats undergoing UUO received a small ventral midline abdominal incision to expose the left kidney and upper ureter.
- the ureter was ligated at the level of the lower pole of the kidney with silk suture and a second time at about 0.2 cm below the first one. Sham operated rats received the same surgical protocol but without ureteral ligation.
- the obstructed rats were treated with PBS, a murine pan-neutralizing monoclonal antibody (1D1 1), an isotype-matched control antibody (13C4), or a human pan- neutralizing TGF- ⁇ monoclonal antibody as disclosed in U.S. Patent No. 7,723,486.
- the antibodies were administered to the rats intraperitoneally beginning on the day of ureteral ligation for a course of 3 weeks.
- 13C4 and 1D1 1 were administered at 5 mg/kg (3 times/week), and the human pan-neutralizing antibody was given to the rats at 5 mg/kg (every 5 days).
- the rats were sacrificed, the kidneys were perfused with PBS for 3 minutes, and the perfused kidneys were harvested for the analysis of mRNA, determination of collagen content, and histological examination.
- total tissue collagen content was determined by biochemical analysis of hydroxyproline in hydrolyzate extracts according to Kivirikko et al.
- a Sircol collagen assay was also performed for total collagen content. The Sircol collagen assay measures the amount of total acid/pepsin soluble collagens based on the specific binding of Sirius red dye with the side chain of tissue collagen.
- the UUO rats treated with the human pan-neutralizing monoclonal antibody showed a 43.4% reduction in hydroxyproline content (1.98 ⁇ 0.26 ⁇ g/mg dry tissue) when compared to the PBS treated group (3.5 ⁇ 0.3 ⁇ g/mg dry tissue, p ⁇ 0.05).
- the lessening in renal fibrosis was further supported by the reduction in total solubilized collagen in the affected kidneys, as determined by a Sirius red dye based assay (sham: 18.5 ⁇ 2.6, PBS: 69.3 ⁇ 3.8, and human pan-neutralizing monoclonal antibody: 35.6 ⁇ 5.2 ⁇ g/100 mg tissue, p ⁇ 0.05 vs. PBS).
- TGF- ⁇ mRNA was reduced in the human pan-neutralizing monoclonal antibody-treated UUO animals compared to either PBS-treated or 13C4 control antibody-treated animals.
- a significant decrease in mRNA levels for type III collagen also was seen in the obstructed kidneys treated with the human and murine anti-TGF- ⁇ antibodies as compared to those treated with PBS or 13 C4 indicating a decrease in collagen synthesis.
- the above-described results demonstrate that the TGF- ⁇ neutralization with a human pan- neutralizing anti-TGF- ⁇ monoclonal antibody interrupted the TGF- ⁇ autocrine-regulation loop concomitant with prevention of TGF- ⁇ production and collagen III mRNA expression.
- the effect of a human pan-neutralizing anti-TGF- ⁇ monoclonal antibody on the expression of smooth muscle actin (a-SMA) was further determined as an indirect indicator of TGF- ⁇ inhibition.
- Smooth muscle actin expression is an indicator of activated myofibroblasts, which are associated with tissue fibrosis and produce fibrous connective tissue.
- TGF- ⁇ is an inducer of the activation and phenotypic transformation of stromal fibroblasts and resident epithelial cells to myofibroblastic cells.
- a-SMA protein was detected by standard Western blot analysis.
- rats with obstructed kidneys showed dramatic up-regulation in a-SMA protein as measured by western blotting of tissue homogenates.
- Obstructed rats dosed with a human pan-neutralizing anti-TGF- ⁇ monoclonal antibody showed significant reduction (75% compared to PBS controls) in measureable a-SMA expression.
- the structure of the 0 ⁇ 008 ⁇ - ⁇ 2 complex was determined as follows. Recombinant GC1008(Fab) with a C-terminal His6 tag (SEQ ID NO: 11) was transiently expressed in HEK293FS cells and purified over Nickel-NTA affinity resin, followed by size exclusion chromatography. The purified GC1008(Fab) was mixed with ⁇ 2 homodimer and the complex was isolated using size exclusion chromatograph. The GC1008(Fab)-TGFp2 complex was crystallized in 35% PEG400, 100 mM 2-(N- morpholino)etlianesulfonic acid (pH 6.0) at 20°C and further optimized by seeding and pH optimization.
- the final data set was collected to 2.83A in space group P2i2j2, and the structure was solved using molecular replacement with the GC1008(Fab)-TGFp3 structure disclosed in Griitter (2008).
- the structure of the GC1008(Fab)-TGFp2 complex is depicted in FIG. 1.
- the structure of the GC1009(scFv)-TGFpi complex was determined as follows. Recombinant GC1009(scFv) with a C-terminus His6 tag (SEQ ID NO: 11) was overexpressed in E. coli and purified over Nickel-NTA affinity resin, followed by size exclusion chromatography. The purified GC1009(scFv) was mixed with TGFpl homodimer, and the complex was isolated using size exclusion chromatograph. The GC1009(scFv)-TGFpl complex was crystallized in 16% PEG 4K, 0.1 M citrate (pH 5.0), 4% 2-propanol at 21°C.
- the structure was determined to 3.00A in space group C2, and the structure was solved using molecular replacement with the GC1008(Fab)-TGFp2 structure determined in EXAMPLE 4.
- the structure of the GC1009(scFv)-TGFpl complex is depicted in FIG. 2.
- EXAMPLE 6 Plasmids encoding either the GC1008 heavy chain or light chain were used as a template in PCR-based mutagenesis reactions. Mutations to the encoding DNA were made to create 155 single amino acid substitutions of the encoded heavy chain amino acid sequence and one single amino acid substitution of the encoded light chain amino acid sequence.
- a QuikChange® Lightning Site-Directed Mutagenesis kit (Agilent Technologies, Santa Clara CA) was used according to the manufacturer's instructions to create DNA mutations using a set of forward and reverse primers, either designed for a specific amino acid or for all 20 amino acids with a degenerate codon (NNK). After sequencing confirmation, identified mutant DNA was paired with a wild-type light or heavy chain DNA for transfection into an Expi293FTM host cell suspension (Life).
- conditioned media (1 mL) was harvested and purified using a 1 mL Protein A PhyTip® column (PhyNexus, Inc., San Jose, CA) and a PureSpeedTM 12-channel pipette (Rainin Instrument LLC, Oakland, CA).
- Purified variant antibody samples were analyzed in duplicate on a Biacore® 3000 (GE Healthcare) at 50 nM concentrations, using the 100 RU level TGFpl, 2, and 3 immobilized surfaces.
- the off-rate (kj) of the variants was divided by the k d of the wild-type control to obtain the fold change in the k d .
- FIG. 5 shows the 3D structure of GC1008 bound to TGFp.
- the gray chain represents GC1008, and the black chain represents TGFp 2.
- Residues 152, 154, and V55 are labeled black letters; residues Y27, S31, N32, and D56 are labeled in gray; and residues S30 and E74 are labeled in white according to the color scheme used for the heat map analysis, shown at the bottom of TABLE 7A.
- An additional six residues labeled in smaller font, P53, N59, G101 , VI 03. LI 04, and A93 are similarly colored according to the heat map analysis.
- the most sensitive positions (152, 154, V55 in black letters) are paratope residues interacting with the core of the completely conserved TGFp hydrophobic patch region, whereas the most tolerant positions (S30, E74 in white letters) are further away and interact with the TGFp helix three region.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL14779440T PL2971048T4 (en) | 2013-03-11 | 2014-03-11 | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
EP18181808.9A EP3415633B1 (en) | 2013-03-11 | 2014-03-11 | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
SI201431071T SI2971048T1 (en) | 2013-03-11 | 2014-03-11 | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
HRP20190201TT HRP20190201T1 (en) | 2013-03-11 | 2019-01-30 | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361776430P | 2013-03-11 | 2013-03-11 | |
PCT/US2014/023274 WO2014164709A2 (en) | 2013-03-11 | 2014-03-11 | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18181808.9A Division EP3415633B1 (en) | 2013-03-11 | 2014-03-11 | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
EP18181808.9A Division-Into EP3415633B1 (en) | 2013-03-11 | 2014-03-11 | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2971048A2 true EP2971048A2 (en) | 2016-01-20 |
EP2971048A4 EP2971048A4 (en) | 2016-11-02 |
EP2971048B1 EP2971048B1 (en) | 2018-10-31 |
Family
ID=51659302
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14779440.8A Active EP2971048B1 (en) | 2013-03-11 | 2014-03-11 | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
EP18181808.9A Active EP3415633B1 (en) | 2013-03-11 | 2014-03-11 | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18181808.9A Active EP3415633B1 (en) | 2013-03-11 | 2014-03-11 | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
Country Status (27)
Country | Link |
---|---|
US (2) | US9783604B2 (en) |
EP (2) | EP2971048B1 (en) |
JP (1) | JP6495884B2 (en) |
KR (1) | KR102258457B1 (en) |
CN (1) | CN105229160B (en) |
AR (1) | AR095240A1 (en) |
AU (2) | AU2014249051B2 (en) |
BR (1) | BR112015021595A2 (en) |
CA (1) | CA2904847C (en) |
CY (1) | CY1121412T1 (en) |
DK (1) | DK2971048T3 (en) |
ES (2) | ES2845215T3 (en) |
HK (1) | HK1220731A1 (en) |
HR (1) | HRP20190201T1 (en) |
HU (1) | HUE042020T2 (en) |
IL (1) | IL241404B (en) |
LT (1) | LT2971048T (en) |
MX (1) | MX365385B (en) |
PL (1) | PL2971048T4 (en) |
PT (1) | PT2971048T (en) |
RU (1) | RU2681502C2 (en) |
SG (2) | SG11201507279XA (en) |
SI (1) | SI2971048T1 (en) |
TR (1) | TR201901415T4 (en) |
TW (2) | TWI664979B (en) |
UY (1) | UY35384A (en) |
WO (1) | WO2014164709A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015027082A1 (en) | 2013-08-22 | 2015-02-26 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
EP3234120A4 (en) | 2014-12-15 | 2018-05-16 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
TWI733661B (en) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY |
TWI726870B (en) * | 2015-03-04 | 2021-05-11 | 美商健臻公司 | scFv-Fc DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY |
CA2994413A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma, Inc. | Methods for treating myeloproliferative disorders |
US11014980B2 (en) | 2015-10-30 | 2021-05-25 | The Regents Of The University Of California | Transforming growth factor-beta-responsive polypeptides and their methods for use |
EP3368579B1 (en) * | 2015-10-30 | 2021-11-24 | F. Hoffmann-La Roche AG | Hinge modified antibody fragments and methods of making |
AU2017268234A1 (en) | 2016-05-17 | 2018-12-13 | Genentech, Inc. | Stromal gene signatures for diagnosis and use in immunotherapy |
GB201610044D0 (en) | 2016-06-08 | 2016-07-20 | Ucb Biopharma Sprl | Antibodies |
WO2018027329A1 (en) * | 2016-08-11 | 2018-02-15 | Precithera, Inc. | TGF-β ANTAGONIST CONJUGATES |
AU2017319702A1 (en) | 2016-09-02 | 2019-04-11 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
HRP20230706T1 (en) | 2017-05-04 | 2023-10-13 | Acceleron Pharma Inc. | Tgf-beta receptor type ii fusion proteins and uses thereof |
WO2019090263A1 (en) | 2017-11-06 | 2019-05-09 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
TW202005981A (en) * | 2018-07-11 | 2020-02-01 | 美商供石公司 | HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF |
US20220119513A1 (en) * | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
US20220162288A1 (en) | 2020-11-25 | 2022-05-26 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
WO2022157773A2 (en) * | 2021-01-21 | 2022-07-28 | Biolojic Design Ltd. | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof |
CN112851819B (en) * | 2021-01-25 | 2023-08-11 | 华中科技大学同济医学院附属同济医院 | Bispecific antibody combined with mouse PD-L1 and TGF-beta, and preparation method and application thereof |
US20240131158A1 (en) | 2021-02-15 | 2024-04-25 | Takeda Pharmaceutical Company Limited | Cell therapy compositions and methods for modulating tgf-b signaling |
CN113480645B (en) * | 2021-07-16 | 2022-11-11 | 甘肃中科博瑞生物工程有限公司 | Anti-helicobacter pylori recombinant antibody, preparation method and application |
WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
WO2024077166A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating lung cancer |
WO2024077095A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
JP4124815B2 (en) | 1991-10-31 | 2008-07-23 | ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ | TGF-β type receptor cDNA and use thereof |
US6008011A (en) | 1991-10-31 | 1999-12-28 | Whitehead Institute For Biomedical Research | TGF-β type II receptor cDNAs |
IL110589A0 (en) | 1993-08-10 | 1994-11-11 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF- beta family |
RU2157406C2 (en) * | 1993-08-10 | 2000-10-10 | Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх | NEW GROWTH/DIFFERENTIATION FACTOR OF TGF-β-FAMILY |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
CA2301166A1 (en) | 1997-07-24 | 1999-02-04 | Yuan-Peng Zhang | Liposomal compositions for the delivery of nucleic acid catalysts |
AU771635B2 (en) | 1999-01-05 | 2004-04-01 | American National Red Cross, The | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
US7763580B2 (en) | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
CA2400628A1 (en) | 2000-03-09 | 2001-09-13 | Genzyme Corporation | Use of tgf-beta antagonists to treat or to prevent loss of renal function |
US20030180301A1 (en) | 2002-01-22 | 2003-09-25 | Shaf Keshavjee | Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection |
WO2004098637A1 (en) | 2003-04-30 | 2004-11-18 | Genzyme Corporation | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
PL3520815T3 (en) | 2005-02-08 | 2022-04-11 | Genzyme Corporation | Antibodies to tgfbeta |
EP1948675B1 (en) | 2005-10-25 | 2014-07-30 | The Johns Hopkins University | Methods and compositions for the treatment of marfan syndrome and associated disorders |
JP5374359B2 (en) | 2006-03-17 | 2013-12-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Stabilized polypeptide compounds |
ES2547333T3 (en) | 2006-04-12 | 2015-10-05 | Genzyme Corporation | Methods to treat autoimmune diseases |
EP2083863B1 (en) | 2006-10-03 | 2015-03-18 | Genzyme Corporation | Antibodies to tgf-beta for use in the treatment of infants at risk of developing bronchopulmonary dysplasia |
US20120294868A1 (en) | 2009-04-24 | 2012-11-22 | Edwards James R | Anti-tgf-beta induction of bone cell function and bone growth |
LT3117709T (en) | 2010-03-12 | 2018-11-26 | Genzyme Corporation | Combination therapy for treating breast cancer |
TR201903101T4 (en) | 2010-09-01 | 2019-03-21 | Genzyme Corp | Treatment of myocardial infarction using TGF-beta antagonists. |
-
2014
- 2014-03-11 SG SG11201507279XA patent/SG11201507279XA/en unknown
- 2014-03-11 DK DK14779440.8T patent/DK2971048T3/en active
- 2014-03-11 TW TW106136054A patent/TWI664979B/en active
- 2014-03-11 KR KR1020157027607A patent/KR102258457B1/en active IP Right Grant
- 2014-03-11 BR BR112015021595A patent/BR112015021595A2/en not_active IP Right Cessation
- 2014-03-11 JP JP2016501191A patent/JP6495884B2/en active Active
- 2014-03-11 LT LTEP14779440.8T patent/LT2971048T/en unknown
- 2014-03-11 ES ES18181808T patent/ES2845215T3/en active Active
- 2014-03-11 EP EP14779440.8A patent/EP2971048B1/en active Active
- 2014-03-11 EP EP18181808.9A patent/EP3415633B1/en active Active
- 2014-03-11 TR TR2019/01415T patent/TR201901415T4/en unknown
- 2014-03-11 CN CN201480026283.5A patent/CN105229160B/en active Active
- 2014-03-11 ES ES14779440T patent/ES2713505T3/en active Active
- 2014-03-11 UY UY0001035384A patent/UY35384A/en not_active Application Discontinuation
- 2014-03-11 AR ARP140100849A patent/AR095240A1/en not_active Application Discontinuation
- 2014-03-11 HU HUE14779440A patent/HUE042020T2/en unknown
- 2014-03-11 PT PT14779440T patent/PT2971048T/en unknown
- 2014-03-11 CA CA2904847A patent/CA2904847C/en active Active
- 2014-03-11 TW TW103108359A patent/TWI613216B/en active
- 2014-03-11 US US14/773,950 patent/US9783604B2/en active Active
- 2014-03-11 AU AU2014249051A patent/AU2014249051B2/en active Active
- 2014-03-11 SI SI201431071T patent/SI2971048T1/en unknown
- 2014-03-11 SG SG10201707021RA patent/SG10201707021RA/en unknown
- 2014-03-11 PL PL14779440T patent/PL2971048T4/en unknown
- 2014-03-11 RU RU2015143156A patent/RU2681502C2/en active
- 2014-03-11 WO PCT/US2014/023274 patent/WO2014164709A2/en active Application Filing
- 2014-03-11 MX MX2015012541A patent/MX365385B/en active IP Right Grant
-
2015
- 2015-09-09 IL IL241404A patent/IL241404B/en active IP Right Grant
-
2016
- 2016-07-20 HK HK16108616.9A patent/HK1220731A1/en unknown
-
2017
- 2017-08-07 US US15/670,631 patent/US10730936B2/en active Active
-
2018
- 2018-05-10 AU AU2018203261A patent/AU2018203261B2/en active Active
-
2019
- 2019-01-30 HR HRP20190201TT patent/HRP20190201T1/en unknown
- 2019-01-31 CY CY20191100139T patent/CY1121412T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018203261B2 (en) | Engineered anti-TGF-beta antibodies and antigen-binding fragments | |
AU2016226098B2 (en) | Modified-IgG antibodies that bind Transforming Growth Factor-Beta1 with high affinity, avidity and specificity | |
US11976112B2 (en) | scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity | |
KR102668864B1 (en) | Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity | |
KR20240076851A (en) | Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20151009 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MOULIN, AARON Inventor name: MATHIEU, MAGALI Inventor name: QIU, HUAWEI Inventor name: PARK, SUNGHAE Inventor name: PAN, CLARK Inventor name: WEI, RONNIE |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20161004 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/395 20060101ALI20160927BHEP Ipc: C07K 16/22 20060101ALI20160927BHEP Ipc: C07K 14/495 20060101ALI20160927BHEP Ipc: C12P 21/08 20060101AFI20160927BHEP Ipc: A61K 39/00 20060101ALI20160927BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1220731 Country of ref document: HK |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MOULIN, AARON Inventor name: QIU, HUAWEI Inventor name: MATHIEU, MAGALI Inventor name: WEI, RONNIE Inventor name: PAN, CLARK Inventor name: PARK, SUNGHAE |
|
INTG | Intention to grant announced |
Effective date: 20180306 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAL | Information related to payment of fee for publishing/printing deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GENZYME CORPORATION |
|
INTC | Intention to grant announced (deleted) | ||
GRAC | Information related to communication of intention to grant a patent modified |
Free format text: ORIGINAL CODE: EPIDOSCIGR1 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAL | Information related to payment of fee for publishing/printing deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR3 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAL | Information related to payment of fee for publishing/printing deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR3 |
|
GRAR | Information related to intention to grant a patent recorded |
Free format text: ORIGINAL CODE: EPIDOSNIGR71 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAL | Information related to payment of fee for publishing/printing deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR3 |
|
GRAR | Information related to intention to grant a patent recorded |
Free format text: ORIGINAL CODE: EPIDOSNIGR71 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
INTG | Intention to grant announced |
Effective date: 20180928 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
INTG | Intention to grant announced |
Effective date: 20180921 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1059423 Country of ref document: AT Kind code of ref document: T Effective date: 20181115 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014035186 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: RO Ref legal event code: EPE Ref country code: HR Ref legal event code: TUEP Ref document number: P20190201 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 2971048 Country of ref document: PT Date of ref document: 20190206 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20190131 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20190201 Country of ref document: HR Payment date: 20190204 Year of fee payment: 6 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20190219 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20190201 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: FG4A Ref document number: E016997 Country of ref document: EE Effective date: 20190220 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20190400378 Country of ref document: GR Effective date: 20190422 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190131 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190228 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2713505 Country of ref document: ES Kind code of ref document: T3 Effective date: 20190522 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181031 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181031 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E042020 Country of ref document: HU |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014035186 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181031 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20190801 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 1059423 Country of ref document: AT Kind code of ref document: T Effective date: 20181031 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20190201 Country of ref document: HR Payment date: 20200204 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LV Payment date: 20200218 Year of fee payment: 7 Ref country code: MC Payment date: 20200226 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MT Payment date: 20200320 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CY Payment date: 20200309 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20190201 Country of ref document: HR Payment date: 20210310 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210311 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210311 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20190201 Country of ref document: HR Payment date: 20220310 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210311 Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181031 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20190201 Country of ref document: HR Payment date: 20230201 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230110 Year of fee payment: 10 Ref country code: DK Payment date: 20230314 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20230310 Year of fee payment: 10 Ref country code: SE Payment date: 20230110 Year of fee payment: 10 Ref country code: PL Payment date: 20230102 Year of fee payment: 10 Ref country code: IT Payment date: 20230213 Year of fee payment: 10 Ref country code: HR Payment date: 20230201 Year of fee payment: 10 Ref country code: BE Payment date: 20230216 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20230405 Year of fee payment: 10 Ref country code: CH Payment date: 20230401 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FI Payment date: 20231219 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20240108 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20190201 Country of ref document: HR Payment date: 20240130 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20240227 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20240213 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LT Payment date: 20240202 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20240103 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20240226 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: RO Payment date: 20240209 Year of fee payment: 11 Ref country code: HU Payment date: 20240205 Year of fee payment: 11 Ref country code: EE Payment date: 20240122 Year of fee payment: 11 Ref country code: DE Payment date: 20231229 Year of fee payment: 11 Ref country code: CZ Payment date: 20240216 Year of fee payment: 11 Ref country code: BG Payment date: 20240125 Year of fee payment: 11 Ref country code: GB Payment date: 20240108 Year of fee payment: 11 Ref country code: SK Payment date: 20240213 Year of fee payment: 11 Ref country code: PT Payment date: 20240311 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SI Payment date: 20240124 Year of fee payment: 11 |